<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511288</url>
  </required_header>
  <id_info>
    <org_study_id>ET15-076 LIBIL</org_study_id>
    <nct_id>NCT02511288</nct_id>
  </id_info>
  <brief_title>LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer</brief_title>
  <acronym>LIBIL</acronym>
  <official_title>Liquid Biopsies in Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Leon Berard</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this project is to characterize the genetic profile of patients with advanced
      stage IIIB/IV non-small cell lung cancer (NSCLC) using liquid biopsies
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancers are the first cause of death by cancer in the world. The majority of these
      patients are diagnosed at a late stage, non-eligible to a curative treatment. Due to tumoral
      genomic identification, it has been possible to classify NSCLC in molecular subtypes
      according to molecular abnormalities detection called &quot;drivers&quot; which can be targeted using
      an appropriate treatment. This change modifies the standard treatments from the very first
      line of treatment particularly for patients having an EGFR mutation or an ALK or ROS1
      rearrangement, with a significant benefit of progression free survival. The French NCI (INCa)
      recommends to identify genomic alterations of a genes panel including EGFR, KRAS, BRAF, HER2,
      ALK and ROS1 as well as mutations in MET exon 14. However, all the patients who benefit from
      a targeted therapy develop resistance after a mean duration of 10-12 months after starting
      the treatment. In case of progression, the tumour genetic analysis through new biopsies,
      enables to identify these mechanisms and then to determine if the patient can benefit or not
      from a third generation molecule active on these mechanisms, and to have a better
      understanding of the disease evolution.

      The detection of these alterations is routinely performed using tissular biopsies but in 10
      to 20% of the cases, it is not possible.

      The detection of these molecular abnormalities in the plasma, called &quot; liquid biopsy &quot; is a
      valuable non-invasive complementary approach for these patients. It is presently used in
      routine for detecting the EGFR mutations at diagnosis as well as for searching EGFR T790M
      mutation for resistant patients.

      The liquid biopsies enable to detect circulating tumoral DNA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 2015</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">March 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identification of the genetic profile in advanced or metastatic NSCLC patients using liquid biopsies (circulating tumoral DNA)</measure>
    <time_frame>5 years</time_frame>
    <description>Technique: ddPCR + targeted NGF, whole exome sequencing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of genetic biomarkers (or molecular profiles) having a potential predictive value in the treatments response</measure>
    <time_frame>5 years</time_frame>
    <description>Techniques: ddPCR + targeted NGF, whole exome sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of the ALK and ROS1 genes translocations in the circulating DNA</measure>
    <time_frame>5 years</time_frame>
    <description>Techniques: ddPCR + targeted NGF, whole exome sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the liquid biopsies role in the tumoral monitoring</measure>
    <time_frame>5 years</time_frame>
    <description>Correlation between mutated allelic fractions or expression's modification with the treatment response. Techniques: ddPCR + targeted NGF, whole exome sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of genomic and transcriptomic factors detectable in the plasma, associated to the immunotherapy response</measure>
    <time_frame>5 years</time_frame>
    <description>Correlation between transcriptomic and genomic factors and response to immunotherapy. Techniques: ddPCR + targeted NGF, whole exome sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the spatial and temporal tumor heterogeneity under targeted therapy treatment</measure>
    <time_frame>5 years</time_frame>
    <description>Techniques: ddPCR + targeted NGF, whole exome sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the miRNAs' expression in plasma as an epigenetic factor associated to treatments response</measure>
    <time_frame>5 years</time_frame>
    <description>Correlation between miRNAS expression in plasma and treatment's efficacy. Techniques: miRNAs profiling using HTG technology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumoral cells isolation and analysis to determine the role of non-genomic and/or phenotypic factors in the treatments response.</measure>
    <time_frame>5 years</time_frame>
    <description>Single cell isolation technology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the resistance mechanisms to targeted therapies</measure>
    <time_frame>5 years</time_frame>
    <description>Technique: ddPCR + targeted NGF, whole exome sequencing</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Patients with advanced NSCLC and no druggable molecular alteration at time of diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <description>Patients with advanced NSCLC harboring targetable molecular alterations at time of diagnosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <description>Patients with advanced NSCLC at time of immunotherapy introduction (1st or 2nd line)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced NSCLC
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        COHORT 1

        Inclusion Criteria:

          -  Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage
             IIIB/IV) regardless of the mutation status

          -  Inclusion at the time of diagnostic

          -  Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the
             institution with an available histopathological report

          -  Age ≥ 18 years

          -  Covered by a health insurance

          -  Signed consent

        Exclusion Criteria:

        - Patients treated before their liquid biopsy

        COHORT 2 Inclusion criteria

          -  Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage
             IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor
             Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor
             Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1
             (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification,
             RET rearrangement.

          -  Inclusion at the time of diagnosis

          -  Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the
             institution with an available histopathological report

          -  Age ≥ 18 years

          -  Covered by a health insurance

          -  Signed consent

        COHORT 3 Inclusion criteria

          -  Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage
             IIIB/IV) whatever the mutational or PD-L1 status.

          -  Inclusion at the time of immunotherapy treatment initiation (1st or 2nd line)

          -  Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the
             institution with an available histopathological report

          -  Age ≥ 18 years

          -  Covered by a health insurance

          -  Signed consent

        Exclusion criteria

        - Initiation of immunotherpy before their liquid biopsy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Saintigny, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>pierre.saintigny@lyon.unicancer.fr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Saintigny, MD, PhD</last_name>
    <email>pierre.saintigny@lyon.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Annecy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphane Hominal, MD</last_name>
      <phone>+33 4.50.63.66.03</phone>
      <email>shominal@ch-annecygenevois.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Fleyriat</name>
      <address>
        <city>Bourg-en-Bresse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascal Beynel, MD</last_name>
      <phone>+33 4.74.45.40.30</phone>
      <email>pbeynel@ch-bourg01.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Louis Pradel</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marylise Ginoux, MD</last_name>
      <phone>+33 4.27.85.77.00</phone>
      <email>marylise.ginoux@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble Alpes</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Moro-Sibilot, MD</last_name>
      <phone>+33 4.76..76.87.08</phone>
      <email>smoro-sibilot@chu-grenoble.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Saintigny, MD-PhD</last_name>
      <phone>+33 478782781</phone>
      <email>pierre.saintigny@lyon.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Saint-Etienne</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire TISSOT, MD</last_name>
      <phone>+33 4.77.82.83.14</phone>
      <email>claire.tissot@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre Fournel, MD</last_name>
      <phone>+33 4.77.91.70.36</phone>
      <email>pierre.fournel@icloire.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Ouest</name>
      <address>
        <city>Villefranche-sur-Saône</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luc Odier, MD</last_name>
      <phone>+33 4.74.09.27.23</phone>
      <email>lodier@lhopitalnordouest.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 16, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hematologic test</keyword>
  <keyword>Liquid biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

